Under construction – not a live service
Sign in
Not yet taking people in TürkiyeNo phase

Neuregulin-4 blood levels in people with type 2 diabetes, with and without obesity

Measures neuregulin-4 in adults with type 2 diabetes, with and without obesity.

Plain-language title generated from the registry record
Registry title: Evaluation of Neuregulin-4 (NRG4) Levels in Obese and Non-Obese Patients With Type 2 Diabetes Mellitus

Key facts

Where
Istanbul, TürkiyeSee the site

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 65 with type 2 diabetes, either newly diagnosed or treated for at least 6 months, plus healthy controls. It studies blood levels of NRG4 in people with and without obesity.

Age
18 to 65 years
Sex
All sexes can join.
Disease stage
Type 2 diabetes, either newly diagnosed without treatment or treated for at least 6 months. BMI above 30 kg/m² or below 25 kg/m².
Earlier treatment
Newly diagnosed people must not have had diabetes treatment before. Others must have been treated for at least 6 months.

Main reasons for not taking part

  • Under 18 years old
  • Pregnancy
  • Breastfeeding
  • Active infection
  • Rheumatologic disease

Read by machine on 13 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Source: NCT07734558, who can take part

Where in Türkiye

  • Kanuni Sultan Süleyman Training and Research HospitalIstanbul, TürkiyeContact: gülden ANATACANo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
GÜLDEN ANATACA
Trial code
NCT07734558
Record updated
29 July 2026
Original description
This prospective observational study aims to evaluate serum Neuregulin-4 (NRG4) concentrations in obese and non-obese adults with Type 2 Diabetes Mellitus (T2DM) and to investigate their association with obesity status, insulin resistance, and different antidiabetic treatment regimens. Participants will be categorized into five predefined groups according to obesity status and treatment regimen, including SGLT2 inhibitor users, non-SGLT2 oral antidiabetic therapy users, SGLT2 combination therapy users, newly diagnosed treatment-naïve patients, and healthy controls. Clinical, anthropometric, and laboratory parameters including fasting plasma glucose, HbA1c, estimated glomerular filtration rate (eGFR), body mass index, waist circumference, waist-to-hip ratio, and serum NRG4 concentrations will be evaluated. The study aims to determine whether NRG4 may serve as a novel biomarker reflecting metabolic status and treatment response in patients with T2DM.Read full original descriptionShow less

Evaluation of the Relationship Between Serum Neuregulin-4 (NRG4) Levels, Obesity Status, and Antidiabetic Treatment Regimens in Patients With Type 2 Diabetes Mellitus: A Prospective Observational Study

This prospective observational study aims to evaluate serum Neuregulin-4 (NRG4) concentrations in obese and non-obese adults with Type 2 Diabetes Mellitus (T2DM) and to investigate their association with obesity status, insulin resistance, and different antidiabetic treatment regimens. Participants will be categorized into five predefined groups according to obesity status and treatment regimen, including SGLT2 inhibitor users, non-SGLT2 oral antidiabetic therapy users, SGLT2 combination therapy users, newly diagnosed treatment-naïve patients, and healthy controls. Clinical, anthropometric, and laboratory parameters including fasting plasma glucose, HbA1c, estimated glomerular filtration rate (eGFR), body mass index, waist circumference, waist-to-hip ratio, and serum NRG4 concentrations will be evaluated. The study aims to determine whether NRG4 may serve as a novel biomarker reflecting metabolic status and treatment response in patients with T2DM.

Inclusion: Age 18-65 years; Newly diagnosed treatment-naïve T2DM; T2DM treated for at least 6 months; BMI >30 kg/m²; BMI <25 kg/m²; No pregnancy; No breastfeeding; No active infection; No inflammatory disease; Written informed consent.

Exclusion: Active infection; Rheumatologic disease; Age <18 years; Pregnancy; Breastfeeding; Refusal to participate.

ClinicalTrials.gov NCT07734558